文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

药物输送系统治疗肌肉减少症的研究进展:最新综述。

Advancements in Drug Delivery Systems for the Treatment of Sarcopenia: An Updated Overview.

机构信息

Department of Surgery, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.

Emergency Hospital Floreasca Bucharest, 014461 Bucharest, Romania.

出版信息

Int J Mol Sci. 2024 Oct 7;25(19):10766. doi: 10.3390/ijms251910766.


DOI:10.3390/ijms251910766
PMID:39409095
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11476378/
Abstract

Since sarcopenia is a progressive condition that leads to decreased muscle mass and function, especially in elderly people, it is a public health problem that requires attention from researchers. This review aims to highlight drug delivery systems that have a high and efficient therapeutic potential for sarcopenia. Current as well as future research needs to consider the barriers encountered in the realization of delivery systems, such as the route of administration, the interaction of the systems with the aggressive environment of the human body, the efficient delivery and loading of the systems with therapeutic agents, and the targeted delivery of therapeutic agents into the muscle tissue without creating undesirable adverse effects. Thus, this paper sets the framework of existing drug delivery possibilities for the treatment of sarcopenia, serving as an inception point for future interdisciplinary studies.

摘要

由于肌肉减少症是一种导致肌肉质量和功能下降的进行性疾病,尤其是在老年人中,因此它是一个需要研究人员关注的公共卫生问题。本综述旨在强调具有高治疗潜力的药物输送系统,可用于治疗肌肉减少症。当前和未来的研究需要考虑在实现输送系统时遇到的障碍,例如给药途径、系统与人体恶劣环境的相互作用、系统高效地输送和加载治疗剂,以及将治疗剂靶向递送至肌肉组织而不产生不良的不良反应。因此,本文为肌肉减少症治疗的现有药物输送可能性设定了框架,为未来的跨学科研究提供了起点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06f7/11476378/59fde4430db3/ijms-25-10766-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06f7/11476378/6b164e1742aa/ijms-25-10766-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06f7/11476378/60252645f5ec/ijms-25-10766-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06f7/11476378/6172e72151ee/ijms-25-10766-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06f7/11476378/f8370785e7bf/ijms-25-10766-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06f7/11476378/59fde4430db3/ijms-25-10766-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06f7/11476378/6b164e1742aa/ijms-25-10766-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06f7/11476378/60252645f5ec/ijms-25-10766-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06f7/11476378/6172e72151ee/ijms-25-10766-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06f7/11476378/f8370785e7bf/ijms-25-10766-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06f7/11476378/59fde4430db3/ijms-25-10766-g005.jpg

相似文献

[1]
Advancements in Drug Delivery Systems for the Treatment of Sarcopenia: An Updated Overview.

Int J Mol Sci. 2024-10-7

[2]
Emerging Therapeutic Strategies in Sarcopenia: An Updated Review on Pathogenesis and Treatment Advances.

Int J Mol Sci. 2024-4-12

[3]
Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies.

Arch Pharm Res. 2024-4

[4]
Sarcopenia: Molecular Pathways and Potential Targets for Intervention.

Int J Mol Sci. 2020-11-22

[5]
Aging of the endocrine system and its potential impact on sarcopenia.

Eur J Intern Med. 2016-7-30

[6]
Sarcopenia: pharmacology of today and tomorrow.

J Pharmacol Exp Ther. 2012-8-28

[7]
Current pharmacotherapies for sarcopenia.

Expert Opin Pharmacother. 2019-5-23

[8]
The role and therapeutic potential of stem cells in skeletal muscle in sarcopenia.

Stem Cell Res Ther. 2022-1-24

[9]
L-Lysine suppresses myofibrillar protein degradation and autophagy in skeletal muscles of senescence-accelerated mouse prone 8.

Biogerontology. 2017-2

[10]
Sarcopenia: An Overview on Current Definitions, Diagnosis and Treatment.

Curr Protein Pept Sci. 2018-5-14

引用本文的文献

[1]
Liposomal and Lipid-Based Drug Delivery Systems: Bridging Gut Microbiota and Pediatric Disorder Treatments.

Pharmaceutics. 2025-5-28

[2]
Revisiting the role of steroidal therapeutics in the 21st century: an update on FDA approved steroidal drugs (2000-2024).

RSC Med Chem. 2025-5-8

[3]
Scientific and Technological Prospecting on Polymeric Particles Containing Extracellular Matrix Peptides for the Treatment of Duchenne Muscular Dystrophy.

Recent Adv Drug Deliv Formul. 2025

本文引用的文献

[1]
AAV-NRIP gene therapy ameliorates motor neuron degeneration and muscle atrophy in ALS model mice.

Skelet Muscle. 2024-7-24

[2]
Low-Frequency Sonophoresis: A Promising Strategy for Enhanced Transdermal Delivery.

Adv Pharmacol Pharm Sci. 2024-6-5

[3]
Oral Drug Delivery via Intestinal Lymphatic Transport Utilizing Lipid-Based Lyotropic Liquid Crystals.

Liquids (Basel). 2023-12

[4]
Emerging Therapeutic Strategies in Sarcopenia: An Updated Review on Pathogenesis and Treatment Advances.

Int J Mol Sci. 2024-4-12

[5]
Advances in Hydrogel-Based Drug Delivery Systems.

Gels. 2024-4-13

[6]
Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies.

Arch Pharm Res. 2024-4

[7]
The Current Landscape of Pharmacotherapies for Sarcopenia.

Drugs Aging. 2024-2

[8]
Ameliorative Effects of Cumin Extract-Encapsulated Chitosan Nanoparticles on Skeletal Muscle Atrophy and Grip Strength in Streptozotocin-Induced Diabetic Rats.

Antioxidants (Basel). 2023-12-19

[9]
Editorial: Non-viral vectors for gene therapy/nucleic acid delivery.

Front Bioeng Biotechnol. 2023-10-31

[10]
Sarcopenia: no consensus, no diagnostic criteria, and no approved indication-How did we get here?

Geroscience. 2024-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索